{"gene":"FANCF","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2000,"finding":"FANCF forms a nuclear complex with FANCA, FANCC, and FANCG in human lymphoblasts. Each FA protein (except FANCD) is required for complex formation, as interactions were detected in wild-type and FA-D cells but not in lymphoblasts of other FA complementation groups.","method":"Subcellular fractionation and co-immunoprecipitation in human lymphoblasts across FA complementation groups","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with genetic validation across multiple complementation groups, replicated across cell lines","pmids":["11063725"],"is_preprint":false},{"year":2004,"finding":"FANCF acts as a flexible adaptor protein in the FA core complex: its C-terminus interacts directly with FANCG to allow assembly of other FA proteins, while the N-terminus stabilizes interactions with FANCA and FANCG and is essential for binding of the FANCC/FANCE subcomplex. FANCF does not have a ROM-like function as previously suggested.","method":"Extensive mutagenesis study guided by human-Xenopus FANCF homology, co-immunoprecipitation of deletion/point mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — systematic domain mutagenesis combined with Co-IP, orthologous sequence comparison, single lab but multiple orthogonal approaches","pmids":["15262960"],"is_preprint":false},{"year":2006,"finding":"X-ray crystallography of the FANCF C-terminal domain reveals a helical repeat structure similar to Cand1, a regulator of a Cul1-Rbx1-Skp1-Fbox ubiquitin ligase complex. Two C-terminal loops are essential for FANCD2 monoubiquitination and cellular resistance to mitomycin C; mutations in this surface abolish interaction with other FA core complex components.","method":"X-ray crystallography of FANCF C-terminal domain; amino acid substitution mutagenesis with FANCD2 monoubiquitination assay and MMC sensitivity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus functional mutagenesis with two orthogonal readouts (FANCD2 ubiquitination, drug sensitivity), single lab","pmids":["17082180"],"is_preprint":false},{"year":2009,"finding":"ICSBP/IRF8 directly activates transcription of FANCF during myeloid differentiation by binding a cis element in the FANCF promoter. ICSBP-deficient myeloid cells show impaired DNA cross-link repair in a FANCF-dependent manner.","method":"Chromatin co-immunoprecipitation to identify FANCF as an ICSBP target gene; FANCF promoter cis-element identification; DNA cross-link repair assay in ICSBP-deficient cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional epistasis (cross-link repair dependent on FANCF in ICSBP-deficient cells), single lab","pmids":["19801548"],"is_preprint":false},{"year":2012,"finding":"FANCF silencing by shRNA blocks FANCD2 monoubiquitination (inactivating the FA/BRCA pathway), inhibits cell proliferation, induces apoptosis and chromosome fragmentation, and sensitizes breast cancer cells to mitoxantrone. Sensitization involves activation of p38 and JNK MAPK pathways; BCRP expression is restored by p38 inhibitor SB203580.","method":"shRNA knockdown of FANCF in MCF-7 and T-47D cells; Western blot for FANCD2 monoubiquitination; MTT proliferation assay; apoptosis assay; p38/JNK pathway inhibitor experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KD with defined molecular readout (FANCD2 ubiquitination) plus pharmacological pathway dissection, single lab, two cell lines","pmids":["22952942"],"is_preprint":false},{"year":2013,"finding":"FANCF silencing by siRNA inactivates the FA/BRCA pathway (decreasing FANCD2 monoubiquitination and focus formation), reduces cell proliferation, induces apoptosis, and sensitizes OVCAR3 ovarian cancer cells to adriamycin through JNK-dependent mitochondrial apoptosis pathway activation.","method":"siRNA knockdown in OVCAR3 cells; FANCD2 monoubiquitination and focus formation by Western blot and immunofluorescence; flow cytometry for apoptosis; JNK pathway inhibitor experiments","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KD with molecular pathway readout, pharmacological validation, single lab; note: paper had figure assembly errors per corrigendum, though conclusions were stated unchanged","pmids":["23440494"],"is_preprint":false},{"year":2023,"finding":"The FANCC-FANCE-FANCF subcomplex is evolutionarily conserved from vertebrates to plants (Arabidopsis). Physical interaction among FANCC, FANCE, and FANCF is conserved, and this subcomplex acts as an anti-crossover factor during meiotic recombination; loss of any of the three genes partially rescues CO-defective mutants and causes synthetic meiotic catastrophe with the pro-CO factor MUS81.","method":"Genetic screen in Arabidopsis; genetic epistasis with CO-defective and MUS81 mutants; co-immunoprecipitation/physical interaction assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in a plant model with physical interaction data; functional conservation demonstrated but mechanistic detail limited to abstract; single study","pmids":["36652992"],"is_preprint":false},{"year":2019,"finding":"Wild-type p53 activates transcription of miR-30c by binding its promoter; miR-30c in turn targets FANCF (and REV1), thereby suppressing FANCF expression. In p53-mutant breast cancer cells, loss of this regulation leads to FANCF upregulation and increased adriamycin resistance.","method":"Luciferase reporter assay for p53 binding to miR-30c promoter; miR-30c overexpression/inhibition with Western blot for FANCF; adriamycin sensitivity assays in p53-WT vs mutant cell lines","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding assay plus miRNA manipulation with defined protein-level readout, single lab","pmids":["31511498"],"is_preprint":false},{"year":2011,"finding":"Fancf-deficient mouse embryonic fibroblasts are unable to monoubiquitinate FANCD2, show G2 arrest, chromosomal aberrations, and reduced survival in response to DNA cross-linking agents, confirming FANCF is required for FANCD2 activation in vivo. Fancf knockout mice show compromised follicle development and spermatogenesis, and increased incidence of ovarian tumors.","method":"Targeted gene disruption (knockout mouse model); Western blot for FANCD2 monoubiquitination; chromosomal aberration assay; survival assay with cross-linking agents; tumor monitoring with aCGH","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple orthogonal functional readouts (FANCD2 ubiquitination, chromosomal aberrations, drug sensitivity, tumor phenotype), in vivo model","pmids":["21915857"],"is_preprint":false}],"current_model":"FANCF is a flexible adaptor protein that localizes to the nucleus and is essential for assembly of the FA core complex by bridging the FANCG subcomplex (via its C-terminus) with the FANCC/FANCE subcomplex (via its N-terminus); its C-terminal helical repeat domain (structurally similar to Cand1) contains two loops critical for FANCD2 monoubiquitination and DNA cross-link repair, and its transcription is directly activated by ICSBP/IRF8 during myeloid differentiation and regulated post-transcriptionally by p53-driven miR-30c."},"narrative":{"mechanistic_narrative":"FANCF is a nuclear adaptor protein essential for assembly of the Fanconi anemia (FA) core complex, which drives monoubiquitination of FANCD2 to enable repair of DNA interstrand cross-links [PMID:11063725, PMID:21915857]. It functions as a flexible bridging subunit: its C-terminus binds FANCG to nucleate assembly of other FA proteins, while its N-terminus stabilizes FANCA/FANCG contacts and is required to recruit the FANCC/FANCE subcomplex [PMID:15262960]. The C-terminal domain adopts a Cand1-like helical repeat fold whose two surface loops are critical both for interaction with other core complex components and for FANCD2 monoubiquitination and cellular resistance to mitomycin C [PMID:17082180]. Loss of FANCF abolishes FANCD2 monoubiquitination and produces G2 arrest, chromosomal aberrations, sensitivity to cross-linking agents, and, in mice, defective gametogenesis and ovarian tumors, establishing its non-redundant role in the FA/BRCA pathway in vivo [PMID:21915857]. The FANCC-FANCE-FANCF subcomplex is evolutionarily conserved to plants, where it additionally acts as an anti-crossover factor during meiotic recombination [PMID:36652992]. FANCF expression is transcriptionally activated by ICSBP/IRF8 during myeloid differentiation [PMID:19801548] and is suppressed by p53-driven miR-30c, such that p53 loss in cancer cells upregulates FANCF and confers chemoresistance [PMID:31511498]; silencing FANCF inactivates the FA/BRCA pathway and sensitizes breast and ovarian cancer cells to chemotherapeutic agents through p38/JNK MAPK signaling [PMID:22952942, PMID:23440494].","teleology":[{"year":2000,"claim":"Established that FANCF is a physical member of a nuclear FA protein complex, placing it within the Fanconi anemia pathway rather than acting alone.","evidence":"Subcellular fractionation and reciprocal Co-IP across FA complementation groups in human lymphoblasts","pmids":["11063725"],"confidence":"High","gaps":["Did not define which domains mediate each interaction","Did not establish the order of complex assembly","No direct link yet to a catalytic output of the complex"]},{"year":2004,"claim":"Resolved FANCF's role as a flexible adaptor that bridges distinct subcomplexes, explaining how it organizes core complex assembly.","evidence":"Systematic deletion/point-mutant Co-IP guided by human-Xenopus homology","pmids":["15262960"],"confidence":"High","gaps":["No structural model of the interacting surfaces","Did not connect adaptor function to FANCD2 modification directly"]},{"year":2006,"claim":"Provided a structural basis for FANCF function by revealing a Cand1-like helical repeat domain and mapping surface loops required for both complex integrity and FANCD2 monoubiquitination.","evidence":"X-ray crystallography of the C-terminal domain plus mutagenesis with FANCD2 ubiquitination and MMC sensitivity readouts","pmids":["17082180"],"confidence":"High","gaps":["Structure limited to the C-terminal domain; full-length and N-terminal architecture unresolved","Mechanistic analogy to Cand1's ubiquitin-ligase regulation not functionally tested"]},{"year":2009,"claim":"Identified an upstream transcriptional input, linking FANCF expression to myeloid differentiation via ICSBP/IRF8.","evidence":"ChIP identification of a FANCF promoter cis-element and cross-link repair epistasis in ICSBP-deficient cells","pmids":["19801548"],"confidence":"Medium","gaps":["Single lab; cis-element not validated by reporter mutagenesis in the timeline","Relevance beyond myeloid lineage unknown"]},{"year":2011,"claim":"Confirmed in vivo that FANCF is required for FANCD2 activation and genome stability, and revealed organismal phenotypes of its loss.","evidence":"Fancf knockout mouse and MEFs assayed for FANCD2 monoubiquitination, chromosomal aberrations, drug sensitivity, and tumor incidence","pmids":["21915857"],"confidence":"High","gaps":["Mechanism linking FA pathway loss to ovarian tumorigenesis not dissected","Tissue-specific gametogenesis defects not mechanistically explained"]},{"year":2012,"claim":"Demonstrated that FANCF depletion is a chemosensitization strategy in breast cancer, coupling FA pathway inactivation to MAPK-driven death.","evidence":"shRNA knockdown in MCF-7/T-47D with FANCD2 ubiquitination Western blot, apoptosis assays, and p38/JNK inhibitor experiments","pmids":["22952942"],"confidence":"Medium","gaps":["Single lab, two cell lines; no in vivo confirmation","Mechanistic link between FA pathway loss and p38/JNK activation unresolved"]},{"year":2013,"claim":"Extended the chemosensitization model to ovarian cancer through JNK-dependent mitochondrial apoptosis.","evidence":"siRNA knockdown in OVCAR3 with FANCD2 ubiquitination/focus readouts, apoptosis flow cytometry, and JNK inhibitor experiments","pmids":["23440494"],"confidence":"Medium","gaps":["Paper had figure assembly errors per corrigendum","Single cell line; mechanism of JNK activation not defined"]},{"year":2019,"claim":"Placed FANCF downstream of a p53–miR-30c axis, explaining how p53 status modulates FANCF levels and chemoresistance.","evidence":"Luciferase reporter for p53 binding to the miR-30c promoter, miR-30c manipulation with FANCF Western blot, and adriamycin sensitivity in p53-WT vs mutant cells","pmids":["31511498"],"confidence":"Medium","gaps":["Single lab; direct miR-30c binding to FANCF transcript not fully mapped","Contribution of co-target REV1 versus FANCF to resistance not separated"]},{"year":2023,"claim":"Revealed a conserved FANCC-FANCE-FANCF subcomplex with a meiotic anti-crossover function, broadening FANCF's role beyond cross-link repair.","evidence":"Genetic screen, epistasis with CO-defective and MUS81 mutants, and physical interaction assays in Arabidopsis","pmids":["36652992"],"confidence":"Medium","gaps":["Mechanistic detail limited; how the subcomplex limits crossovers not defined","Conservation of the meiotic anti-crossover role in mammals not demonstrated in the timeline"]},{"year":null,"claim":"How the Cand1-like FANCF domain mechanistically couples core complex assembly to the FANCD2 ubiquitin ligase activity, and how this links to its meiotic anti-crossover function, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No full-length structure of FANCF within the assembled core complex","Molecular basis of the anti-crossover activity unknown","Mechanism connecting FA pathway loss to p38/JNK signaling undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,2]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[2,8]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[6,8]}],"complexes":["Fanconi anemia core complex","FANCC-FANCE-FANCF subcomplex"],"partners":["FANCA","FANCC","FANCG","FANCE"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NPI8","full_name":"Fanconi anemia group F protein","aliases":[],"length_aa":374,"mass_kda":42.3,"function":"DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NPI8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FANCF","classification":"Not Classified","n_dependent_lines":219,"n_total_lines":1208,"dependency_fraction":0.18129139072847683},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FANCF","total_profiled":1310},"omim":[{"mim_id":"613984","title":"FANCD2 GENE; FANCD2","url":"https://www.omim.org/entry/613984"},{"mim_id":"613976","title":"FANCE GENE; FANCE","url":"https://www.omim.org/entry/613976"},{"mim_id":"613899","title":"FANCC GENE; FANCC","url":"https://www.omim.org/entry/613899"},{"mim_id":"613897","title":"FANCF GENE; FANCF","url":"https://www.omim.org/entry/613897"},{"mim_id":"609644","title":"FANCM GENE; FANCM","url":"https://www.omim.org/entry/609644"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FANCF"},"hgnc":{"alias_symbol":["FAF"],"prev_symbol":[]},"alphafold":{"accession":"Q9NPI8","domains":[{"cath_id":"-","chopping":"1-67_80-149","consensus_level":"medium","plddt":76.7984,"start":1,"end":149},{"cath_id":"1.25.40.490","chopping":"157-212_232-245","consensus_level":"medium","plddt":84.6814,"start":157,"end":245},{"cath_id":"1.25.40.490","chopping":"256-363","consensus_level":"medium","plddt":89.9231,"start":256,"end":363}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NPI8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NPI8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NPI8-F1-predicted_aligned_error_v6.png","plddt_mean":78.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FANCF","jax_strain_url":"https://www.jax.org/strain/search?query=FANCF"},"sequence":{"accession":"Q9NPI8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NPI8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NPI8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NPI8"}},"corpus_meta":[{"pmid":"11063725","id":"PMC_11063725","title":"The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11063725","citation_count":167,"is_preprint":false},{"pmid":"15126331","id":"PMC_15126331","title":"Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15126331","citation_count":160,"is_preprint":false},{"pmid":"15574200","id":"PMC_15574200","title":"CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.","date":"2004","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15574200","citation_count":75,"is_preprint":false},{"pmid":"17932744","id":"PMC_17932744","title":"Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.","date":"2007","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/17932744","citation_count":70,"is_preprint":false},{"pmid":"12781358","id":"PMC_12781358","title":"FANCF methylation contributes to chemoselectivity in ovarian cancer.","date":"2003","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12781358","citation_count":60,"is_preprint":false},{"pmid":"16418574","id":"PMC_16418574","title":"Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.","date":"2006","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16418574","citation_count":58,"is_preprint":false},{"pmid":"14617007","id":"PMC_14617007","title":"Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia.","date":"2003","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/14617007","citation_count":54,"is_preprint":false},{"pmid":"15262960","id":"PMC_15262960","title":"The Fanconi anemia gene product FANCF is a flexible adaptor protein.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15262960","citation_count":53,"is_preprint":false},{"pmid":"18414472","id":"PMC_18414472","title":"Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.","date":"2008","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18414472","citation_count":41,"is_preprint":false},{"pmid":"22297615","id":"PMC_22297615","title":"Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line.","date":"2012","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22297615","citation_count":37,"is_preprint":false},{"pmid":"17082180","id":"PMC_17082180","title":"Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17082180","citation_count":34,"is_preprint":false},{"pmid":"21915857","id":"PMC_21915857","title":"Fancf-deficient mice are prone to develop ovarian tumours.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21915857","citation_count":29,"is_preprint":false},{"pmid":"30822218","id":"PMC_30822218","title":"Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.","date":"2019","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30822218","citation_count":25,"is_preprint":false},{"pmid":"31511498","id":"PMC_31511498","title":"Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31511498","citation_count":22,"is_preprint":false},{"pmid":"22952942","id":"PMC_22952942","title":"Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22952942","citation_count":21,"is_preprint":false},{"pmid":"36652992","id":"PMC_36652992","title":"The FANCC-FANCE-FANCF complex is evolutionarily conserved and regulates meiotic recombination.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36652992","citation_count":20,"is_preprint":false},{"pmid":"19801548","id":"PMC_19801548","title":"The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19801548","citation_count":18,"is_preprint":false},{"pmid":"24345874","id":"PMC_24345874","title":"RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.","date":"2013","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/24345874","citation_count":12,"is_preprint":false},{"pmid":"28440438","id":"PMC_28440438","title":"Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.","date":"2017","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28440438","citation_count":12,"is_preprint":false},{"pmid":"25647473","id":"PMC_25647473","title":"Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/25647473","citation_count":12,"is_preprint":false},{"pmid":"19813073","id":"PMC_19813073","title":"Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.","date":"2009","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/19813073","citation_count":12,"is_preprint":false},{"pmid":"23440494","id":"PMC_23440494","title":"RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23440494","citation_count":9,"is_preprint":false},{"pmid":"31288759","id":"PMC_31288759","title":"A novel frame-shift deletion in FANCF gene causing autosomal recessive Fanconi anemia: a case report.","date":"2019","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31288759","citation_count":7,"is_preprint":false},{"pmid":"26033879","id":"PMC_26033879","title":"Clinical aspects of Fanconi anemia individuals with the same mutation of FANCF identified by next generation sequencing.","date":"2015","source":"Birth defects research. Part A, Clinical and molecular teratology","url":"https://pubmed.ncbi.nlm.nih.gov/26033879","citation_count":6,"is_preprint":false},{"pmid":"28612587","id":"PMC_28612587","title":"– (-) Menthol Induces Reversal of Promoter Hypermethylation and Associated Up-Regulation of the FANCF Gene in the SiHa Cell Line.","date":"2017","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/28612587","citation_count":5,"is_preprint":false},{"pmid":"16803569","id":"PMC_16803569","title":"No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia.","date":"2006","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16803569","citation_count":5,"is_preprint":false},{"pmid":"36369330","id":"PMC_36369330","title":"Genetic analysis of a Fanconi anemia case revealed the presence of FANCF mutation (exon 1;469>C-T) with implications to develop acute myeloid leukemia.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36369330","citation_count":2,"is_preprint":false},{"pmid":"27714961","id":"PMC_27714961","title":"Phenotypic variability in patients with Fanconi anemia and biallelic FANCF mutations.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27714961","citation_count":2,"is_preprint":false},{"pmid":"35543152","id":"PMC_35543152","title":"[Corrigendum) RNA interference‑mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin‑induced apoptosis dependent on JNK activation.","date":"2022","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35543152","citation_count":2,"is_preprint":false},{"pmid":"32915143","id":"PMC_32915143","title":"FANCF hypomethylation is associated with colorectal cancer in Han Chinese.","date":"2020","source":"The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32915143","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.06.28.24309592","title":"Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort","date":"2024-06-30","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.28.24309592","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16348,"output_tokens":2416,"usd":0.042642,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9565,"output_tokens":3178,"usd":0.063637,"stage2_stop_reason":"end_turn"},"total_usd":0.106279,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"FANCF forms a nuclear complex with FANCA, FANCC, and FANCG in human lymphoblasts. Each FA protein (except FANCD) is required for complex formation, as interactions were detected in wild-type and FA-D cells but not in lymphoblasts of other FA complementation groups.\",\n      \"method\": \"Subcellular fractionation and co-immunoprecipitation in human lymphoblasts across FA complementation groups\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with genetic validation across multiple complementation groups, replicated across cell lines\",\n      \"pmids\": [\"11063725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FANCF acts as a flexible adaptor protein in the FA core complex: its C-terminus interacts directly with FANCG to allow assembly of other FA proteins, while the N-terminus stabilizes interactions with FANCA and FANCG and is essential for binding of the FANCC/FANCE subcomplex. FANCF does not have a ROM-like function as previously suggested.\",\n      \"method\": \"Extensive mutagenesis study guided by human-Xenopus FANCF homology, co-immunoprecipitation of deletion/point mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — systematic domain mutagenesis combined with Co-IP, orthologous sequence comparison, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"15262960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"X-ray crystallography of the FANCF C-terminal domain reveals a helical repeat structure similar to Cand1, a regulator of a Cul1-Rbx1-Skp1-Fbox ubiquitin ligase complex. Two C-terminal loops are essential for FANCD2 monoubiquitination and cellular resistance to mitomycin C; mutations in this surface abolish interaction with other FA core complex components.\",\n      \"method\": \"X-ray crystallography of FANCF C-terminal domain; amino acid substitution mutagenesis with FANCD2 monoubiquitination assay and MMC sensitivity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus functional mutagenesis with two orthogonal readouts (FANCD2 ubiquitination, drug sensitivity), single lab\",\n      \"pmids\": [\"17082180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ICSBP/IRF8 directly activates transcription of FANCF during myeloid differentiation by binding a cis element in the FANCF promoter. ICSBP-deficient myeloid cells show impaired DNA cross-link repair in a FANCF-dependent manner.\",\n      \"method\": \"Chromatin co-immunoprecipitation to identify FANCF as an ICSBP target gene; FANCF promoter cis-element identification; DNA cross-link repair assay in ICSBP-deficient cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional epistasis (cross-link repair dependent on FANCF in ICSBP-deficient cells), single lab\",\n      \"pmids\": [\"19801548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FANCF silencing by shRNA blocks FANCD2 monoubiquitination (inactivating the FA/BRCA pathway), inhibits cell proliferation, induces apoptosis and chromosome fragmentation, and sensitizes breast cancer cells to mitoxantrone. Sensitization involves activation of p38 and JNK MAPK pathways; BCRP expression is restored by p38 inhibitor SB203580.\",\n      \"method\": \"shRNA knockdown of FANCF in MCF-7 and T-47D cells; Western blot for FANCD2 monoubiquitination; MTT proliferation assay; apoptosis assay; p38/JNK pathway inhibitor experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KD with defined molecular readout (FANCD2 ubiquitination) plus pharmacological pathway dissection, single lab, two cell lines\",\n      \"pmids\": [\"22952942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FANCF silencing by siRNA inactivates the FA/BRCA pathway (decreasing FANCD2 monoubiquitination and focus formation), reduces cell proliferation, induces apoptosis, and sensitizes OVCAR3 ovarian cancer cells to adriamycin through JNK-dependent mitochondrial apoptosis pathway activation.\",\n      \"method\": \"siRNA knockdown in OVCAR3 cells; FANCD2 monoubiquitination and focus formation by Western blot and immunofluorescence; flow cytometry for apoptosis; JNK pathway inhibitor experiments\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KD with molecular pathway readout, pharmacological validation, single lab; note: paper had figure assembly errors per corrigendum, though conclusions were stated unchanged\",\n      \"pmids\": [\"23440494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The FANCC-FANCE-FANCF subcomplex is evolutionarily conserved from vertebrates to plants (Arabidopsis). Physical interaction among FANCC, FANCE, and FANCF is conserved, and this subcomplex acts as an anti-crossover factor during meiotic recombination; loss of any of the three genes partially rescues CO-defective mutants and causes synthetic meiotic catastrophe with the pro-CO factor MUS81.\",\n      \"method\": \"Genetic screen in Arabidopsis; genetic epistasis with CO-defective and MUS81 mutants; co-immunoprecipitation/physical interaction assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in a plant model with physical interaction data; functional conservation demonstrated but mechanistic detail limited to abstract; single study\",\n      \"pmids\": [\"36652992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Wild-type p53 activates transcription of miR-30c by binding its promoter; miR-30c in turn targets FANCF (and REV1), thereby suppressing FANCF expression. In p53-mutant breast cancer cells, loss of this regulation leads to FANCF upregulation and increased adriamycin resistance.\",\n      \"method\": \"Luciferase reporter assay for p53 binding to miR-30c promoter; miR-30c overexpression/inhibition with Western blot for FANCF; adriamycin sensitivity assays in p53-WT vs mutant cell lines\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding assay plus miRNA manipulation with defined protein-level readout, single lab\",\n      \"pmids\": [\"31511498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Fancf-deficient mouse embryonic fibroblasts are unable to monoubiquitinate FANCD2, show G2 arrest, chromosomal aberrations, and reduced survival in response to DNA cross-linking agents, confirming FANCF is required for FANCD2 activation in vivo. Fancf knockout mice show compromised follicle development and spermatogenesis, and increased incidence of ovarian tumors.\",\n      \"method\": \"Targeted gene disruption (knockout mouse model); Western blot for FANCD2 monoubiquitination; chromosomal aberration assay; survival assay with cross-linking agents; tumor monitoring with aCGH\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple orthogonal functional readouts (FANCD2 ubiquitination, chromosomal aberrations, drug sensitivity, tumor phenotype), in vivo model\",\n      \"pmids\": [\"21915857\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FANCF is a flexible adaptor protein that localizes to the nucleus and is essential for assembly of the FA core complex by bridging the FANCG subcomplex (via its C-terminus) with the FANCC/FANCE subcomplex (via its N-terminus); its C-terminal helical repeat domain (structurally similar to Cand1) contains two loops critical for FANCD2 monoubiquitination and DNA cross-link repair, and its transcription is directly activated by ICSBP/IRF8 during myeloid differentiation and regulated post-transcriptionally by p53-driven miR-30c.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FANCF is a nuclear adaptor protein essential for assembly of the Fanconi anemia (FA) core complex, which drives monoubiquitination of FANCD2 to enable repair of DNA interstrand cross-links [#0, #8]. It functions as a flexible bridging subunit: its C-terminus binds FANCG to nucleate assembly of other FA proteins, while its N-terminus stabilizes FANCA/FANCG contacts and is required to recruit the FANCC/FANCE subcomplex [#1]. The C-terminal domain adopts a Cand1-like helical repeat fold whose two surface loops are critical both for interaction with other core complex components and for FANCD2 monoubiquitination and cellular resistance to mitomycin C [#2]. Loss of FANCF abolishes FANCD2 monoubiquitination and produces G2 arrest, chromosomal aberrations, sensitivity to cross-linking agents, and, in mice, defective gametogenesis and ovarian tumors, establishing its non-redundant role in the FA/BRCA pathway in vivo [#8]. The FANCC-FANCE-FANCF subcomplex is evolutionarily conserved to plants, where it additionally acts as an anti-crossover factor during meiotic recombination [#6]. FANCF expression is transcriptionally activated by ICSBP/IRF8 during myeloid differentiation [#3] and is suppressed by p53-driven miR-30c, such that p53 loss in cancer cells upregulates FANCF and confers chemoresistance [#7]; silencing FANCF inactivates the FA/BRCA pathway and sensitizes breast and ovarian cancer cells to chemotherapeutic agents through p38/JNK MAPK signaling [#4, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that FANCF is a physical member of a nuclear FA protein complex, placing it within the Fanconi anemia pathway rather than acting alone.\",\n      \"evidence\": \"Subcellular fractionation and reciprocal Co-IP across FA complementation groups in human lymphoblasts\",\n      \"pmids\": [\"11063725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Did not define which domains mediate each interaction\",\n        \"Did not establish the order of complex assembly\",\n        \"No direct link yet to a catalytic output of the complex\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved FANCF's role as a flexible adaptor that bridges distinct subcomplexes, explaining how it organizes core complex assembly.\",\n      \"evidence\": \"Systematic deletion/point-mutant Co-IP guided by human-Xenopus homology\",\n      \"pmids\": [\"15262960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural model of the interacting surfaces\",\n        \"Did not connect adaptor function to FANCD2 modification directly\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided a structural basis for FANCF function by revealing a Cand1-like helical repeat domain and mapping surface loops required for both complex integrity and FANCD2 monoubiquitination.\",\n      \"evidence\": \"X-ray crystallography of the C-terminal domain plus mutagenesis with FANCD2 ubiquitination and MMC sensitivity readouts\",\n      \"pmids\": [\"17082180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structure limited to the C-terminal domain; full-length and N-terminal architecture unresolved\",\n        \"Mechanistic analogy to Cand1's ubiquitin-ligase regulation not functionally tested\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified an upstream transcriptional input, linking FANCF expression to myeloid differentiation via ICSBP/IRF8.\",\n      \"evidence\": \"ChIP identification of a FANCF promoter cis-element and cross-link repair epistasis in ICSBP-deficient cells\",\n      \"pmids\": [\"19801548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab; cis-element not validated by reporter mutagenesis in the timeline\",\n        \"Relevance beyond myeloid lineage unknown\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Confirmed in vivo that FANCF is required for FANCD2 activation and genome stability, and revealed organismal phenotypes of its loss.\",\n      \"evidence\": \"Fancf knockout mouse and MEFs assayed for FANCD2 monoubiquitination, chromosomal aberrations, drug sensitivity, and tumor incidence\",\n      \"pmids\": [\"21915857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism linking FA pathway loss to ovarian tumorigenesis not dissected\",\n        \"Tissue-specific gametogenesis defects not mechanistically explained\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that FANCF depletion is a chemosensitization strategy in breast cancer, coupling FA pathway inactivation to MAPK-driven death.\",\n      \"evidence\": \"shRNA knockdown in MCF-7/T-47D with FANCD2 ubiquitination Western blot, apoptosis assays, and p38/JNK inhibitor experiments\",\n      \"pmids\": [\"22952942\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab, two cell lines; no in vivo confirmation\",\n        \"Mechanistic link between FA pathway loss and p38/JNK activation unresolved\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended the chemosensitization model to ovarian cancer through JNK-dependent mitochondrial apoptosis.\",\n      \"evidence\": \"siRNA knockdown in OVCAR3 with FANCD2 ubiquitination/focus readouts, apoptosis flow cytometry, and JNK inhibitor experiments\",\n      \"pmids\": [\"23440494\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Paper had figure assembly errors per corrigendum\",\n        \"Single cell line; mechanism of JNK activation not defined\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed FANCF downstream of a p53–miR-30c axis, explaining how p53 status modulates FANCF levels and chemoresistance.\",\n      \"evidence\": \"Luciferase reporter for p53 binding to the miR-30c promoter, miR-30c manipulation with FANCF Western blot, and adriamycin sensitivity in p53-WT vs mutant cells\",\n      \"pmids\": [\"31511498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab; direct miR-30c binding to FANCF transcript not fully mapped\",\n        \"Contribution of co-target REV1 versus FANCF to resistance not separated\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a conserved FANCC-FANCE-FANCF subcomplex with a meiotic anti-crossover function, broadening FANCF's role beyond cross-link repair.\",\n      \"evidence\": \"Genetic screen, epistasis with CO-defective and MUS81 mutants, and physical interaction assays in Arabidopsis\",\n      \"pmids\": [\"36652992\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanistic detail limited; how the subcomplex limits crossovers not defined\",\n        \"Conservation of the meiotic anti-crossover role in mammals not demonstrated in the timeline\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the Cand1-like FANCF domain mechanistically couples core complex assembly to the FANCD2 ubiquitin ligase activity, and how this links to its meiotic anti-crossover function, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No full-length structure of FANCF within the assembled core complex\",\n        \"Molecular basis of the anti-crossover activity unknown\",\n        \"Mechanism connecting FA pathway loss to p38/JNK signaling undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [2, 8]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"complexes\": [\n      \"Fanconi anemia core complex\",\n      \"FANCC-FANCE-FANCF subcomplex\"\n    ],\n    \"partners\": [\n      \"FANCA\",\n      \"FANCC\",\n      \"FANCG\",\n      \"FANCE\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}